ArticleCancer medicine2016
Flow cytometry-based characterization of underlying clonal B and plasma cells in patients with light chain amyloidosis.
Article in Cancer medicine, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Diagnostic utility of immunofixation and free light chain assay in AL amyloidosis: a systematic review and meta-analysis.Blood advances · 2026Pooled it
- American Society of Hematology 2026 guidelines on diagnosis of light chain amyloidosis.Blood advances · 2026Guideline
- Detection of minimal residual disease by next generation sequencing in AL amyloidosis.Blood cancer journal · 2021Trial
- Assessment of minimal residual disease using multiparametric flow cytometry in patients with AL amyloidosis.Blood advances · 2020Trial
- Diagnostic value of bone marrow smear for amyloid detection and its correlation with clinical features in systemic light-chain amyloidosis.Scientific reports · 2026Article
- Proving Bone Marrow Plasma Cell Clonality by Flow Cytometry: An Important Tool in the Diagnosis of Immunoglobulin Light-Chain Amyloidosis.Biomedicines · 2025Article
- Cardiac amyloidosis: evolving pathogenesis, multimodal diagnostics, and principles of treatment.EXCLI journal · 2023Review
- Article
- Minimal residual disease negativity by next-generation flow cytometry is associated with improved organ response in AL amyloidosis.Blood cancer journal · 2021Article
- Performance analysis of AL amyloidosis cardiac biomarker staging systems with special focus on renal failure and atrial arrhythmia.Haematologica · 2019Article
- Emerging Therapeutics for the Treatment of Light Chain and Transthyretin Amyloidosis.JACC. Basic to translational science · 2019Review
- Flow cytometry for fast screening and automated risk assessment in systemic light-chain amyloidosis.Leukemia · 2019Article
- Prognostic significance of circulating plasma cells by multi-parametric flow cytometry in light chain amyloidosis.Leukemia · 2018Article
- Current applications of multiparameter flow cytometry in plasma cell disorders.Blood cancer journal · 2017Review
- Clinical Relevance of Multicolour Flow Cytometry in Plasma Cell Disorders.Indian journal of hematology & blood transfusion : an official journal of Indian Society of Hematology and Blood Transfusion · 2017Review
- Minimal residual disease (MRD) assessment by flow cytometry after ASCT for AL amyloidosis: are we there yet?Bone marrow transplantation · 2017Article
- Flow cytometry-based characterization of underlying clonal B and plasma cells in patients with light chain amyloidosis.Cancer medicine · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Systemic amyloid light chain (AL) amyloidosis is a life-threatening protein deposition disorder; however, effective therapy can dramatically improve the prognosis of AL patients. Therefore, accurate diagnosis of the underlying hematologic disease is important. Multi-parameter flow cytometry (MFC) is a reliable method to analyze lymphatic neoplasias and to detect even a small lymphatic clone. We analyzed the presence of clonal plasma cell (PC) and B cells in the bone marrow of 63 patients with newly diagnosed AL amyloidosis by MFC. We compared the results with the levels of monoclonal protein, the histopathology and cytogenetic results. As reference of light chain restriction, we used the immunohistochemical results of κ or λ positive amyloid deposits in various tissues. MFC identified underlying clonal lymphatic cells in all but two patients (61 of 63, 97%). Sixty-one patients harbored malignant PCs, whereas B-cell lymphomas were identified in two patients. Furthermore, MFC indicated at least one putative immunotherapeutical target (CD20, CD38, CD52, or SLAMF7) on malignant PCs in all but one patient. These results demonstrate that MFC is a reliable tool for an accurate diagnosis of the underlying hematologic disease and the detection of potential immunotherapeutical targets in patients with AL amyloidosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.